Alzamend Neuro Shares Outstanding History (ALZN)
Alzamend Neuro reported 4.3M shares outstanding at the end of fiscal 2026.
View full Alzamend Neuro company overviewAlzamend Neuro annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | 4.3M | 3.5M | +446.53% |
| 2025 | 2025-04-30 | 778,733 | 702,289 | +918.70% |
| 2024 | 2024-04-30 | 76,444 | −569,823 | −88.17% |
| 2023 | 2023-04-30 | 646,267 | −94.8M | −99.32% |
| 2022 | 2022-04-30 | 95.5M | 28.1M | +41.60% |
| 2021 | 2021-04-30 | 67.4M | 2.7M | +4.12% |
| 2020 | 2020-04-30 | 64.8M | — | — |
Alzamend Neuro quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | 4.3M | 3.5M | +446.53% |
| Q3 2026 | 2026-01-31 | 3.8M | −2.0M | −34.37% |
| Q2 2026 | 2025-10-31 | 3.8M | −1.4M | −27.33% |
| Q1 2026 | 2025-07-31 | 3.1M | 2.3M | +264.54% |
| Q4 2025 | 2025-04-30 | 778,733 | 90,734 | +13.19% |
| Q3 2025 | 2025-01-31 | 5.8M | −821,932 | −12.42% |
| Q2 2025 | 2024-10-31 | 5.2M | −1.2M | −19.14% |
| Q1 2025 | 2024-07-31 | 861,332 | −96.1M | −99.11% |
| Q4 2024 | 2024-04-30 | 687,999 | −96.3M | −99.29% |
| Q3 2024 | 2024-01-31 | 6.6M | −89.8M | −93.14% |
| Q2 2024 | 2023-10-31 | 6.5M | −89.0M | −93.23% |
| Q1 2024 | 2023-07-31 | 96.9M | 1.5M | +1.53% |
| Q4 2023 | 2023-04-30 | 96.9M | 1.5M | +1.53% |
| Q3 2023 | 2023-01-31 | 96.4M | 9.5M | +10.98% |
| Q2 2023 | 2022-10-31 | 95.5M | 28.1M | +41.62% |
| Q1 2023 | 2022-07-31 | 95.5M | 30.7M | +47.43% |
| Q4 2022 | 2022-04-30 | 95.5M | — | — |
| Q1 2022 | 2021-07-31 | 86.9M | — | — |
| Q4 2021 | 2021-04-30 | 67.4M | — | — |
| Q4 2020 | 2020-04-30 | 64.8M | — | — |
Alzamend Neuro shares outstanding trends
Over the last five reported fiscal years, Alzamend Neuro's shares outstanding moved from 67.4M to 4.3M, a change of −63.2M. The latest reported quarter, Q4 2026, shows 4.3M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alzamend Neuro filings at SEC.gov ↗